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Objective 
To assess the long-term efficacy of intestinal transplantation 
under tacrolimus-based immunosuppression and the thera-
peutic benefit of newly developed adjunct immunosuppres-
sants and management strategies. 
Summary Background Data 
With the advent of tacrolimus in 1990, transplantation of the 
intestine began to emerge as therapy for intestinal failure. 
However, a high risk of rejection, with the consequent need 
for acute and chronic high-dose immunosuppression, has 
inhibited its widespread application. 
Methods 
During an 11-year period, divided into two segments by a 
1-year moratorium in 1994, 155 patients received 165 intesti-
nal allografts under immunosuppression based on tacrolimus 
and prednisone: 65 intestine alone, 75 liver and intestine, and 
25 multivisceral. For the transplantations since the morato-
rium (n = 99), an adjunct immunosuppressant (cyclophos-
It has been only 14 years since the first scattered exam-
ples were recorded of extended survival in humans of nu-
trition-supporting intestinal allografts transplanted under 
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phamide or daclizumab) was used for 74 transplantations, 
adjunct donor bone marrow was given in 39, and the intestine 
of 11 allografts was irradiated with a single dose of 750 cGy. 
Results 
The actuarial survival rate for the total population was 75% at 
1 year, 54% at 5 years, and 42% at 10 years. ReCipients of 
liver plus intestine had the best long-term prognosis and the 
lowest risk of graft loss from rejection (P = .001). Since 1994, 
survival rates have improved. Techniques for early detection 
of Epstein-Barr and cytomegaloviral infections, bone marrow 
augmentation, the adjunct use of the interleukin-2 antagonist 
daclizumab, and most recently allograft irradiation may have 
contributed to the better results. 
Conclusion 
The survival rates after intestinal transplantation have cumula-
tively improved during the past decade. With the manage-
ment strategies currently under evaluation, intestinal trans-
plant procedures have the potential to become the standard 
of care for patients with end-stage intestinal failure. 
cyclosporine-based immunosuppression.I-6 Then, with the 
advent of tacrolimus in 1989 to 1990/,8 clinical intestinal 
transplantation began to emerge as a practical means of 
treating intestinal failure. 9- 15 Multiple factors have sus-
tained and increased these efforts, including technical inno-
vations in surgery and improvements in nonspecific post-
operative care, 
The most important therapeutic achievement, however, 
has been the increasingly efficient prevention and/or control 
of rejection, exemplified by our experience reported here 
with 155 recipients of 165 intestinal, liver-intestinal, or 
multivisceral abdominal allografts whose transplantations 
were performed between May 2, 1990, and February 18, 
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200 I. The emphasis in this analysis will be placed on the 
long-term outlook of patients who were still alive at the time 
of previous reports, and on attempts to improve the prog-
nosis with new adjunct immunosuppressants or manage-
ment strategies that have yielded promising results in lab-
oratory models. 
METHODS 
Recipients 
Sixty-two of the 155 recipients were treated between May 
2, 1990, and early 1994. At the end of this time, we 
discontinued the program for nearly 1 year because of the 
seemingly fixed high death rate and excessive complication 
rates. In the analysis presented to the American Surgical 
Association in 1995,12 six statistically significant risk fac-
tors were identified, of which three were immunosuppres-
sion-specific: excessively high blood levels of tacrolimus, 
the use of large intravenous boluses of prednisone, and the 
frequent administration of the monoclonal antilymphoid 
globulin OKT3. The other three risk factors were the dura-
tion of the intestinal transplant operations, inclusion in the 
allograft of segments of donor colon in continuity with the 
small bowel, and a cytomegalovirus (CMV) carrier state of 
the organ donor when the intestinal allografts were trans-
planted to CMV-negative recipients. When the moratorium 
was lifted and the program reopened, reforms designed to 
lessen the impact of these risks were instituted. To compare 
the results before and after the moratorium, the demo-
graphic features of the recipient populations in the two eras 
were determined and were found to be similar (Table I). 
Allografts 
One hundred fifty-five primary transplantations and 10 
retransplantations of the three different kinds of allografts 
shown in Figure 1 were carried out during the II-year 
period. Eighty-four children with a mean age of 4.9 ±: 4.8 
years received 89 of the allografts, 73% of which consisted 
of liver plus intestine or of multiple abdominal viscera 
rather than intestine only. Interestingly, three ofthe children 
who received primary intestinal allografts were previous 
hepatic allograft recipients who had developed intestinal 
failure 4 to 10 years after liver transplantation because of 
midgut volvulus (n = 2) or the hollow visceral myopathy/ 
neuropathy syndrome (n = 1). The 71 adult recipients of76 
allografts were 38 ±: II years old. In contrast to the 27% 
incidence of pediatric recipients of intestine-only allografts, 
54% of the transplantations in adult patients were of this 
variety. 
Biochemical or histologic evidence of hepatic dysfunc-
tion was present in many of our 62 intestine-alone recipi-
ents. However, our policy throughout, in both adults and 
children, was to transplant only the intestine if damage to 
the liver was thought to be reversible. Retention of the 
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Table 1. CLINICAL FEATURES 
1990-1994 1995-2001 Total 
Total no. of patients 62 93 155 
Children/adults 34/28 50/43 84/71 
Prior abdominal operations 3:!:3 4:!:4 4:!:4 
Operative time (h) 14 :!: 3 14 :!: 4 14:!: 4 
Total no. of allografts 66 99 165 
Intestine 23 (35%) 42 (42%) 65 (39%) 
Composite 43 (65%) 57 (58%) 100 (61%) 
Cold ischemia time (h) 8:!:2 10:!: 2 9:!:3 
Positive cross-match 12 (18%) 23 (23%) 35 (21%) 
Bone marrow augmentation 0(0%) 39 (39%) 39 (24%) 
Intestinal irradiation 0(0%) 11 (11 %) 11 (7%) 
Induction therapy 
No 66 (100%) 25 (25%) 91 (55%) 
Yes 0(0%) 74 (75%) 74 (45%) 
Splenectomy 30 (45%) 25 (25%) 55 (33%) 
OKT3 24 (36%) 36 (36%) 60 (36%) 
CMV status (donor/recipient) 
Positive/negative 17 (26%) 18 (18%) 35 (21%) 
Positive/positive 8 (12%) 12 (12%) 20 (12%) 
Negative/positive 14(21%) 23 (23%) 37 (22%) 
Negative/negative 27(41%) 46 (47%) 73 (44%) 
CMV, cytomegalovirus. 
damaged but salvageable native liver was not an exclusive 
feature of the intestine-alone recipient. In 5 of the 25 mul-
tivisceral transplantations, the native liver was not excised. 
Instead, the donor liver was removed from the superior end 
of the multi visceral allografts and used for other patients. 
This modification of conventional multivisceral transplan-
tation has the advantage of permitting all of the hollow 
intraabdominal viscera to be transplanted in continuity and 
vascularized from a single vascular pedicle (Figs. 2, 3). 
The 10 retransplantations in the 155 recipients were per-
formed with isolated intestine (n = 3), liver plus intestine 
(n = 4), and multiple abdominal viscera (n = 3). The three 
intestine-alone retransplantations were performed 3, 16, and 
330 days after graft enterectomy for chronic rejection. Two 
of the four liver-intestinal allografts were used to rescue 
primary intestine-only recipients, 6 and 660 days after graft 
enterectomy, and the other two were used to replace acutely 
failing primary liver-intestinal allografts. The three multi-
visceral grafts were retransplanted to recipients whose fail-
ing primary intestinal, liver-intestinal, and multivisceral 
transplants had been transplanted 94, 455, and II days 
previously. 
The short gut syndrome was the cause of intestinal failure 
in 82% of the cases. Loss of the intestine in adults was due 
most commonly to thrombotic disorders, Crohn's disease, 
and trauma, and in children to volvulus, gastroschisis, ne-
crotizing enterocolitis, and intestinal atresia. Most of the 
thrombotic disorders were due to protein C, S, and anti-
thrombin III deficiency, factor VIII mutation, and develop-
ment of lupus anticoagulant or anti cardiolipin antibodies. 
Indications other than the absence of bowel included dys-
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Figure 1. The yearly number and 
kinds of intestinal transplant proce-
dures performed since 1990. Note 
the 1994 moratorium. 
• Multlvlsceral 
OLiver-Intestine 
• Isolated Intestine 
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motility syndromes (9%), intestinal neoplasm (6%), and 
enterocyte failure (3%). 
The most common reason for the use of composite (Le., 
intestine-liver or multivisceral) allografts was liver failure 
induced by total parenteral nutrition (TPN; mean bilirubin 
19 mgldL). Consequently, the list of underlying etiologies 
of intestinal failure largely overlapped the causes of liver 
failure. With hepatic failure, most of the candidates for 
composite visceral transplantation were classified as IIA 
(intensive care unit-bound) or lIB in the United Network for 
Organ Sharing (UNOS) candidacy listing. 
Donors 
With the exception of an O-blood-type liver-intestine 
transplanted to an A-blood-type recipient under urgent cir-
cumstances, the cadaveric donor and recipient types were 
identical. Human leukocyte antigen (HLA) matching was 
random and uniformly poor, with no examples of zero -A, 
-B, -DR mismatches. The T-cell lymphocytotoxic cross-
match was positive after dithiothreitol (DTT) treatment in 
35 (21%) of the patients; 12 were compiled before the 
moratorium of 1994 (see Table 1). Of the subsequent 23 
cross-match-positive recipients, 19 were treated at the time 
of surgery with adjunct cyclophosphamide (n = 7) or da-
clizumab (n = 12) in addition to the tacrolimus and pred-
nisone therapy used throughout (Table 2). 
Because of the adverse effect of positive donor CMV 
serology on outcome reported in 1995,12 an attempt was 
made to avoid the use of CMV -positive donors for CMV-
negative intestine-alone or modified multivisceral recipi-
ents. This policy was considered impractical for patients 
Year of Transplant 
whose need for liver-intestinal or full multivisceral grafts 
was generally too urgent to tolerate delays. 
Donor Procedures 
Details of the procurement technique for the three differ-
ent types of intestinal allografts have been described be-
fore,6.16 including the technique used for 16 of the 65 
intestine-only allografts in which the liver, pancreas, and 
intestine from the same donor were transplanted to three 
different recipients. 17 To reduce postoperative graft dysmo-
tility,18 the enteric and celiac ganglia were preserved in the 
last 49 composite grafts (since February 1996). In another 
modification designed to avoid the potential risks of biliary 
reconstruction and to reduce the operating time, the duode-
num was retained in continuity with the graft jejunum and 
biliary system in 29 liver-intestinal grafts;19.20 in 6 of these, 
the donor pancreas was left intact. In four intensive care 
unit-bound children, a left lateral segment (n = 1) or a 
reduced-size liver (n = 3) in combination with donor intes-
tine were used after an in situ or ex vivo splifo.21 to 
overcome a mismatch between donor and recipient size. 
The allografts were infused in situ with University of 
Wisconsin (UW) solution and immersed in UW solution for 
storage. Cold ischemia times ranged from 2.8 to 17 (mean 
9 ± 3) hours and were significantly (P = .0001) shorter 
before 1994 (7.7 ± 2.1 hours) than after the moratorium 
(9.8 ± 2.3 hours) (see Table 1). Grafts transplanted under 
tacrolimus and prednisone immunosuppression only (i.e., 
without adjunct induction therapy) had a significantly (P = 
.004) shorter ischemia time than those transplanted to pa-
tients given perioperative cyclophosphamide or daclizumab 
(see Table 2). There was no significant (P = .9) difference 
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Figure 2. Transplantation of a modified multivisceral graft (unshaded 
organs) containing the pancreas and all of the hollow intraabdominal 
viscera in continuity from the esophagogastric junction to the terminal 
ileum. The native liver, spleen, pancreas, and a C loop of duodenum 
have been retained. The procedure was used to treat a patient with 
pseudoobstruction. Biliary drainage from the native liver as well as from 
both pancreases was accomplished with a side-to-side host-to-graft 
duodenal anastomosis. The insert shows preservation of the donor 
splenic (OSA) and left gastric (OLGA) arteries (with Carrel patch) with 
ligation of the donor hepatic artery (OHA) stump. Note that an interpo-
sition arterial graft was initially anastomosed to the recipient infrarenal 
aorta and before allograft implantation. RSA, recipient splenic artery; 
RSV, recipient splenic vein; RBO, recipient bile duct; RPV, recipient 
portal vein; OSMV, donor superior mesenteric vein; OSMA, donor su-
perior mesenteric artery. 
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between ischemia times in the adjunct cyclophosphamide 
versus the daclizumab subsets. 
Recipient Operations 
The principles6 and details of the three intestinal trans-
plant procedures9-11.22-25 have been reported elsewhere. In 
all, an effort is made to reconstruct the vascular inflow, 
venous outflow, and exocrine drainage of the individual 
organs as normally as possible. However, compromises have 
been necessary. For example, although venous effluent from 
both the intestine and pancreas has hepatotrophic qualities and 
ideally should have first passage through the sinusoidal bed of 
the liver,26 this was achievable with only 41 (63%) of the 65 
small bowel allografts. In the other 37%, it was necessary to 
divert the nutrient-rich blood to the host vena cava. 
Similarly, the insulin-rich effluent from the native pan-
creas was diverted around the transplanted liver in 60 (80%) 
of the liver-intestine recipients. As a temporary expedient in 
all patients, portacaval shunt between the host portal vein 
and inferior vena cava was routinely performed to avoid the 
acute portal hypertension caused by splanchnic venous 
cross-clamping during insertion of the liver-intestinal allo-
grafts. Although these shunts were systematically taken 
down in our initial experience to selectively deliver the 
insulin-rich blood to the transplanted liver, the shunts have 
been left in place since 1995 in preference to accepting the 
risk associated with their surgical disconnection and anas-
tomosing the host portal vein to the side of the allograft 
portal vein. 
Such problems have been minimized in recent modifica-
tions of the multivisceral procedure that have found a spe-
cial niche in the treatment of patients in whom the native 
liver and possibly the pancreas and spleen can be retained 
with the host. After the full multivisceral graft is procured, 
the donor liver is removed for separate use in another 
Table 2. COMPARISON OF IMMUNOSUPPRESSIVE PROPHYLAXIS 
Total no. of patients 
Children/adults 
No. of abdominal operations 
Operative time (h) 
Total no. of allografts 
Intestine 
Liver-intestine 
Multivisceral 
Cold ischemia time (h) 
Positive cross-match 
Bone marrow augmentation 
Intestinal irradiation 
Tacrolimus-
Prednisone 
Only 
83 
48/35 
3±3 
14 ± 4 
91 
33(36%) 
44(48%) 
14 (16%) 
8.4 ± 3 
16 (18%) 
12 (13%) 
0(0%) 
• The last 18 of these 48 patients also were treated with rapamycin. 
Adjunct Therapy With 
Cyclophosphamide 
24 
12/12 
5±4 
13 ± 4 
24 
10 (42%) 
11 (46%) 
3 (12%) 
9.7:!: 2.3 
7(29%) 
9(38%) 
0(0%) 
Daclizumab* 
48 
20/28 
5±5 
14 ± 3 
50 
22 (44%) 
20 (40%) 
8(16%) 
9.5 ± 2 
12 (24%) 
18(36%) 
11 (22%) 
------------------------------------
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Figure 3. The use of a modified multivisceral graft (stomach, duode-
num, pancreas, and small bowel) after abdominal visceral exenteration 
with preservation of the host liver and spleen (shaded organs). The 
portosplenic circulation is maintained intact during graft insertion and 
the preserved spleen protects the patient from the risk of posttransplant 
Iymphoproliferative disease. This modified multivisceral transplantation 
has been used to treat recipients with massive gastrointestinal polypo-
sis and extensive Crohn's disease. Note the duct-to-duct biliary recon-
struction. RSA, recipient splenic artery; RSV, recipient splenic vein; 
RBD, recipient bile duct; DSA, donor splenic artery; DLGA, donor left 
gastric artery; DBD, donor bile duct. 
recIpient. Two versions of this modified operation are 
shown in Figures 2 and 3. The procedure has been used for 
the indications described in the captions. 
Immunosuppression 
All recipients were treated primarily with tacrolimus and 
steroids (Table 3). Prostaglandin El was infused intrave-
nously during the first postoperative week to all but the first 
eight recipients. A 4-week course of 2 to 3 mglkg/day 
cyclophosphamide (Cytoxan) was added to the treatment of 
24 recipients of primary allografts between May 3, 1995, 
and November 2, 1997, and replaced for the following 2 to 
3 months by mycophenolate mofetil (15-30 mglkg/day) or 
azathioprine (50-100 mg/day). 
Daclizumab (Zenapax), a humanized IgGI monoclonal 
antibody directed at the a subunit of the human interleu-
kin-2 receptor, was used as the third agent between May 31, 
1998, and February 18,2001, for recipients of 48 primary 
Ann. Surg .• September 2001 
Table 3. BONE MARROW-AUGMENTED 
VERSUS CONTROL RECIPIENTS 
Bone Control 
Marrow Recipients 
Total no. of patients 38 56 
Children/adults 18/20 33/23 
Male/female 18/20 32/24 
Primary grafts 37 (95%) 56(93%) 
Total no. of allografts 39 60 
Intestine 19(49%) 23 (38%) 
Composite 20 (51%) 37 (62%) 
No. of abdominal operations 5±5 4±4 
Operative time (h) 14 ± 5 14 ± 3 
Cold ischemia time (h) 10 ± 3 10 ± 2 
Positive cross-match 7 (18%) 16 (27%) 
Induction therapy 27 (69%) 45 (75%) 
Intestinal irradiation 9(24%) 2(3%) 
allografts and 2 retransplants. Five intravenous doses of I to 
2 mg/kg were given. The first was given a few hours before 
surgery; the remaining four doses were given after 2, 4, 6, and 
8 weeks, except in three patients in whom the drug was 
discontinued after two doses because of unexplained abdomi-
naVgastrointestinal bleeding and hematuria. In addition to ad-
junct daclizumab, rapamycin (Rapamune) was used as a fourth 
drug for the first 3 to 6 months in the last 18 patients, beginning 
in adults with 5 mg/day for 2 weeks and 3 mg/day thereafter, 
and in children with 1 to 2 mg/m2/day for 2 weeks and 
appropriate downward adjustments thereafter. 
Rejection episodes were treated with a steroid bolus and 
a 5-day dose taper, with adjustment of the daily tacrolimus 
dose to achieve higher trough levels. OKT3 or thymoglobu-
lin was used throughout to treat steroid-resistant and severe 
rejection episodes. The effect of the adjunct drugs (cyclo-
phosphamide, daclizumab) on the doses of the baseline 
agents (Le., tacrolimus and prednisone) for the first year is 
shown in Figure 4. Patients treated with daclizumab tended 
to have lower doses of both tacrolimus and prednisone, an 
effect that may have reflected the coadministration of siroli-
mus in 18 of these 48 patients. 
Bone Marrow Augmentation 
With informed consent from both donor families and 
recipients, bone marrow cells were recovered from the 
thoracolumbar vertebrae of the intestinal donors and infused 
intravenously into the organ recipients at the time of sur-
gery.27-29 A single infusion of 3 to 5 X 108 donor cells/kg 
was given over 20 minutes within the first 12 hours after 
revascularization of 19 isolated intestine grafts and 20 com-
posite grafts (see Table 3). The bone marrow cells were not 
available for 60 contemporaneous intestinal recipients who 
were considered to be prospective contemporaneous con-
trols. Except for two patients in the bone marrow group and 
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Figure 4. Tacrolimus whole blood 12-hour trough levels and tacroli-
mus and prednisone doses in recipients who received tacrolimus and 
prednisone only and those who received an adjunct induction therapy 
with either cyclophosphamide or daclizumab. 
four controls, the bowel transplantations were primary. The 
clinical features of both cohorts are summarized in Table 3. 
Ex Vivo Graft Irradiation 
On April 20, 2000, a clinical trial of low-dose ex vivo 
intestinal allograft irradiation was initiated in adults. The 
intestine of 11 allografts (6 intestine only, 1 liver-intestine, 
and 4 multivisceral) given to 10 primary recipients was 
irradiated on the back table with a single dose of 750 cGy. 
Donor bone marrow cells were given to nine of these 
recipients (see Table 3). 
Nutritional Management and Infection 
Prophylaxis 
As described elsewhere, the achievement of full nutri-
tional autonomy has required flexible and complex meta-
bolic and surgical management strategies, particularly for 
recipients of multivisceral grafts.9,ll,30,31 Antimicrobial 
prophylaxis and active treatment of viral, bacterial, and 
fungal infections also are critical. I1 ,l9,32 Since 1994, the 
newly developed technique of semiquantitative polymerase 
chain reaction (PCR) assay of Epstein-Barr virus (EBV) in 
the peripheral blood has allowed early detection, treatment, 
and monitoring of EBV infestation.33 Similarly, the PP65 
antigenemia test that has been used to early detect CMV 
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reactivation or de novo infection has improved the preemp-
tive treatment of this virus. As an adjunct to ganciclovir, 
CMV-specific hyperimmune globulin (Cytogam) has been 
added to the early postoperative antiviral prophylaxis for 
high-risk patients. 19,34 
Immunologic Monitoring 
Acute rejection of the intestinal allograft was diagnosed 
by histopathologic studies of endoscopically guided multi-
ple mucosal biopsies, usually of the ileum, that were ob-
tained when indicated by clinical judgment rather than by 
protocol. Chronic rejection was diagnosed on the basis of 
histologic examination of full-thickness enteric specimens. 
The criteria for the diagnoses of acute and chronic rejection 
have been standardized by Demetris et al. 35 
To assess for graft-versus-host disease (GVHD), biopsy 
samples of recipient skin and native gastrointestinal tract 
were examined histopathologically and with immunocyto-
chemical techniques that allowed the identification of donor 
leukocytes with the in situ hybridization technique using the 
Y -chromosome-specific probe or the immunohistologic 
staining of donor-specific HLA antigens. Other GVHD tar-
get organs also were closely observed and biopsy samples 
were taken when indicated. 
Statistical Analysis 
All analyses were performed using SPSS (SPSS Inc., 
Chicago, IL) for Windows software. Data were prospec-
tively collected for the total population and updated to 
February 28, 2001. All variables were pooled at first and 
then stratified according to year of transplant, immunosup-
pressive regimen, bone marrow augmentation, and type of 
allograft. Data analyses in the patients treated with adjunct 
bone marrow were compared with the results obtained in 
contemporaneous controls. Continuous variables were re-
ported as mean ::!:: standard deviation and categorical data as 
proportions. Differences in group means were tested using 
the standard two-sample t test and one-way analysis of 
variance. Differences in proportions were tested by the 
Fisher exact test and chi-square analysis. The five multivis-
ceral grafts that did not contain a liver were excluded from 
any comparative analysis between isolated intestine and 
composite grafts. 
The mean values for the tacrolimus and steroid doses as 
well as the measured 12-hour tacrolimus whole blood 
trough levels were collected for each patient at 7 days, 1 
month, 3 months, 6 months, 12 months, and every year 
after. The values were pooled for each cohort and the means 
were calculated and compared at each study point. 
Patient and graft survival curves were generated using the 
Kaplan-Meier methods,36,37 and group comparisons were 
done using the log-rank test.38 The isolated intestinal recip-
ients who were discharged from the hospital after total graft 
enterectomy were censored at the time of their graft removal 
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Figure 5. Kaplan-Meier patient and graft survival curves for the total 
population. 
(n = 5). The cumulative risks of graft loss from rejection, 
posttransplant Iymphoproliferative disease (PTLD), and 
CMV were estimated using the Kaplan-Meier method. 
RESULTS 
Survival 
The Kaplan-Meier actuarial survival rate for the total 
population was 75% at 1 year, 54% at 5 years, and 42% at 
10 years (Fig. 5). Most of the deaths occurred within the 
first 3 postoperative years, from causes summarized in Ta-
ble 4, and 30 recipients (9 isolated intestine, 15 liver-
intestine, 6 multi visceral) survived beyond the 5-year mile-
stone. Eighty-three (53.6%) of the 155 recipients are 
currently alive, 7 of whom have returned to TPN and are 
waiting for either isolated intestinal (n = 6) or liver-intes-
tinal transplants (n = 1). The remaining 76 (49%) current 
survivors (34 adults, 42 children) still bear functioning 
grafts after a mean follow-up of 43 ± 40 months (range 
0.3-129). Twenty of these (4 intestine alone, 13 liver-
intestine, and 3 multi visceral) have survived for more than 
5 years with functioning allografts. A liver-intestine recip-
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Figure 6. Kaplan-Meier survival curves of the three different types of 
intestinal grafts. 
ient at 129 months and a multivisceral recipient at 114 
months have the longest surviving functional grafts of these 
kinds in the world. Recipients of liver-intestinal allografts 
had the best prognosis for continued survival beyond 5 
years (Fig. 6). 
Patient as well as graft survival rates improved since 
1994 compared with the premoratorium experience (Fig. 7). 
The I-year actuarial patient survival rates in the early cohort 
of 62 recipients were 71% at 1 year and 43% at 5 years, 
versus 78% and 63% in the 93 recipients of the post-1994 
period (P = .03). Because of the complexity of the cases 
and of the treatment strategies, the reasons for the improve-
ment must be considered indeterminate. In addition to the 
core regimen of tacrolimus and prednisone, all but 21 of the 
93 patients in the postmoratorium group were treated with 
adjunct immunosuppressants: cyclophosphamide (n = 24), 
daclizumab (n = 48), or rapamycin (n = 18). Moreover, 38 
recipients of 39 intestinal allografts were infused with donor 
bone marrow cells. Finally, 6 of the intestine-alone allo-
grafts as well as the intestinal component of 4 multivisceral 
and 1 liver-intestinal grafts were subjected to ex vivo irra-
diation, and 9 of those 11 allografts belonged to the group 
of 39 infused with donor bone marrow cells (see Table 3). 
Table 4. CAUSE OF DEATH AFTER INTESTINAL TRANSPLANTATION 
Infection Rejection PTLD Technical Others 
Isolated intestine (n = 62) 11 (18%)" 2(3%) 0(0%) 0(0%) 12 (19%) 
Liver-intestine (n = 71) 11 (15%) 5(7%) 4(6%) 9(13%) 5(7%) 
Multivisceral (n = 22) 6(27%) 1 (5%) 5(23%) 0(0%) 1 (5%) 
Total (155) 28 (18%) 8(5%) 9(6%) 9(6%) 18 (12%) 
PTLD, posttransplant Iymphoproliferative disease . 
• 5 had undergone graft enterectomy. 
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Figure 7. Patient (A) and graft (8) survival rates before and after the 1994 moratorium. 
Although therapeutic efficacy cannot be definitively claimed 
for any of these modifications of conventional tacrolimus and 
prednisone immunosuppression, several observations are note-
worthy. First, the I-year actuarial survival rate in the 48 pa-
tients treated with daclizumab was 86% (P = .3) with a graft 
survival of 82% (P = .2). Second, the 1- and 5-year recipient 
survival rates in the bone marrow-augmented group were 79% 
and 74%, with a graft survival rate of 68% and 62% (Fig. 8), 
respectively. Finally, aUlD recipients of 11 irradiated allografts 
are well as of Feb. 28, 2001. The lost irradiated graft was 
because of poor donor selection. 
Rejection 
The incidence of rejection during the first 30 postopera-
tive days was significantly (P = .02) higher among patients 
who were transplanted during 1990 to 1994 (85%) than in 
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those transplanted during 1995 to 2001 (67%). The use of 
daclizumab appeared to be the principal factor in reducing 
the incidence of early posttransplant rejection during the 
second era despite lower tacrolimus trough levels (Fig. 9). 
Refractory rejection was the primary cause of failure of 
32 (19%) of the 165 grafts: 24 intestine only, 6 liver-
intestine, and 2 multivisceral for an overall incidence of 
37%,8%, and 8% for the three kinds of grafts, respectively. 
The cumulative risk ofloss from acute and chronic rejection 
of the 65 intestine-only allografts was significantly greater 
than that of the 95 composite visceral grafts that contained 
liver (P = .00001) (Fig. 10). Moreover, the risk of intestine-
only graft loss from rejection was not significantly reduced 
in the second phase of our experience compared with the 
first (data not shown), confirming an ominous observation 
that we first reported in 1998.19 
~ 
-1 
~ 50 
:::J (I) 40 
= I! 
~ 
,--, 
-I 
1- _____ , 
P=0.8 
-- Bone Marrow Augmented (n=39) 
- - Control (n=60) 
1 2 3 4 5 
Time After Transplantation (year) 
Figure 8. Patient (A) and graft (8) survival rates for the bone marrow-augmented and control groups. 
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Figure 9. Tacrolimus whole blood 12-hour trough levels and tacroli-
mus and prednisone doses in the patients who were transplanted be-
fore and after the 1994 moratorium. 
Chronic rejection was diagnosed in 18 grafts (15 intestine 
alone, 3 liver-intestine) from 69 to 2,877 days after trans-
plantation (median 236). The diagnosis was made in 15 
instances by histopathologic examination of enterectomy 
specimens and in the 16th by examination of an autopsy 
liver-intestine specimen. In the remaining two recipients of 
liver-intestinal gmfts, the diagnosis was made on the basis 
of oblitemted submucosal blood vessels in endoscopic mu-
cosal biopsy specimens. 
The cumulative risk of chronic rejection was significantly 
(P = .00001) greater among the isolated intestinal grafts 
compared with the composite grafts that contained liver, 
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Figure 10. Cumulative risk of graft loss from rejection in the intestine-
only and composite visceral grafts that contained liver. 
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with 1- and 5-year rates of 12% and 31 % versus 1.5% and 
7%, respectively. With bone marrow augmentation, chronic 
rejection was diagnosed in only one (2.7%) primary intes-
tine-only graft that was removed 1,951 days after transplan-
tation. In contrast, six (11%) of the control grafts (four 
isolated intestine, two liver-intestine) developed chronic 
rejection at 87 to 1,785 days from the date of primary 
tmnsplantation. Ofthese six recipients, four underwent graft 
enterectomy, one died with graft in place, and the remaining 
one is currently alive with mild graft dysfunction. 
Graft-Versus-Host Disease 
Skin changes suggestive of GVHD were clinically ob-
served in 13 (8.4%) of the patients but histologically doc-
umented in only 7 (4.5%). Two of the seven received 
intestine-only grafts and the other five received composite 
visceml grafts. GVHD was lethal in only one previously 
reported liver-intestinal recipient who had preexisting IgA 
deficiency.39 Another patient, an adult multivisceral recipi-
ent, developed chronic GVHD of his tongue and buccal 
mucosa and eventually died of disseminated PTLD.19 
The disease was self-limited in the other five patients, 
three of whom had received adjunct donor bone marrow and 
developed mild to moderate msh 30, 188, and 312 days after 
liver-intestinal tmnsplantation. The latter three patients, as 
well as another isolated intestinal recipient, responded to an 
increase in daily steroid and tacrolimus doses. The fifth 
recipient experienced transient GVHD 6 days after graft 
enterectomy and withdmwal of immunosuppression be-
cause of the development of PTLD. 
Graft Enterectomy and 
Retransplantation 
Twenty-three (35%) of the 65 intestine-only allografts 
were removed from 20 recipients (12 adults, 8 children) 
663 ::!: 831 days after transplantation (mnge 9 days to 102 
months). Irreversible acute (n = 10) and chronic rejection 
(n = 8) was the indication for 18 (78%) of the 23 graftec-
tomies. In the remaining five patients, the grafts were re-
moved after discontinuance of immunosuppression because 
of PTLD (n = 2), neuronal demyelinization (n = 1), re-
fractory CMV retinitis (n = 1), and extensive bilobar 
Pseudomonas pneumonia (n = 1). Retmnsplantation was 
performed in 6 of the 20 patients 3 to 667 days (median 39) 
after their graft enterectomy. The retransplantations were 
with intestine alone (n = 3), liver-intestine (n = 2), and a 
multivisceml gmft (n = 1). One of the liver-intestine recip-
ients is well after 428 days. One of the intestine-alone 
recipients had gmft function for 1,176 days before chronic 
rejection necessitated return to TPN; after another 687 days, 
he awaits a third transplantation. The other four retmnsplant 
recipients lost their secondary allografts within a few days 
to 5 months, and only one survived to return to TPN. Ofthe 
other 17 patients whose intestine-only grafts were excised 
-.. ,---~--,-.---" ,,-,-
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Figure 11. Cumulative risk of posttransplant Iymphoproliferative disease (PTLD) according to era (A) and 
bone marrow augmentation (8). 
without retransplantation, 4 died of sepsis soon after their 
enterectomies, 5 died later of TPN-related complications, 
and 8 are alive and receiving TPN 5 to 82 months after graft 
removal. 
Two of the 71 primary liver-intestine recipients had their 
failing grafts replaced at 30 and 59 days; a third received a 
multi visceral graft 455 days after the primary liver-intestine 
procedure. The first of these patients is well 45 months after 
retransplantation, but the second and third died after 45 and 
60 days from intractable acute rejection and PTLD, 
respectively. 
One of the 22 primary multivisceral recipients underwent 
full replacement of a poorly functioning primary graft after 
11 days and is currently alive with a fully functioning graft 
161 days later. 
Virus-Associated Syndromes 
In the 1995 analysis of the first 71 intestinal recipients of 
this series, the high death rates associated with EBV-asso-
ciated B-cell lymphomas (also known as PTLD) and with 
disseminated CMV infections loomed as singularly impor-
tant impediments to further progress in the intestinal trans-
plantation field. With the techniques of early detection of 
CMV and EBV, management of these infections has been 
markedly facilitated. 
Thirty (19%) of the 155 patients developed PTLD, 18 
before and 12 after the 1994 moratorium. Although the 
cumulative 5-year rate of PTLD was 15% in the second era 
(half of the earlier 33% rate; Fig. IlA), the disease fatality 
was only 8% versus the earlier 44%. Young age (P = .001), 
type of intestinal graft (multivisceral) (P = .08), and recip-
ient splenectomy (P = .006) continued to be significant risk 
factors for development of PTLD, as previously reported. 19 
Contrary to predictions,4o the 7% I-year cumulative risk of 
PTLD was lower in the patients given adjunct donor bone 
marrow than the 20% in the control patients (Fig. liB). 
None of the patients who received irradiated intestinal al-
lografts has developed PTLD. 
Similarly, the early diagnosis of CMV infection and 
prompt preemptive therapy has significantly (P = .05) re-
duced the risk of CMV disease (Fig. 12). Even with the 
nearly unrestricted use of CMV-positive donors (see Table 
1), there have been no CMV-associated deaths since 1994. 
Hospitalization and Nutritional 
Rehabilitation 
The mean duration of intensive care unit stay was signif-
icantly (P = .004) reduced from 29 :t: 44 days between 
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Figure 12. Cumulative risk of cytomegaloviral (CMV) disease among 
patients who were transplanted before and after the 1994 moratorium. 
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1990 and 1994 to 16 ± 23 days for patients between 1995 
and 200 I. The total hospital stay also was significantly (P = 
.0001) reduced from a mean of 12 ± 8.7 to 5.7 ± 4.7 weeks. 
Most of the reductions in hospital times resulted from an 
improved speed of recovery, including the intestinal allo-
graft absorptive function. Complete discontinuation of TPN 
in the I 995-to-200 I recipients after a median of 20 days 
(mean 27 ± 22) was in striking contrast to the 42-day 
median (mean 55 ± 45) of the earlier era (P = .0001). 
None of the 37 recipients who had primary chronic dis-
ease of the native intestine, including 14 with Crohn's 
disease, have had any clinical or histopathologic evidence of 
recurrence in the intestinal transplant. Seventy-one (93%) of 
the 76 current survivors with graft in place are completely 
off TPN with full nutritional autonomy, enjoying an unre-
stricted oral diet. The remaining five patients are receiving 
partial TPN and on a temporary basis because of systemic 
chemotherapy (n = 1), a recent episode of rejection (n = I), 
postoperative recovery from exploratory laparotomy for de 
novo mesenteric pseudotumor (n = 1), and recent transplant 
(n = 1). 
DISCUSSION 
Two factors accounted for the long delay in the develop-
ment of intestinal transplantation relative to that of the other 
vital organs. First, the general perception until well into the 
1990s was that GVHD mounted by the lymphoid-rich bowel 
was going to be a common problem,41 similar to that which 
plagued clinical bone marrow transplantation.42 Second, it 
was assumed that translocation of microorganisms from the 
intestinal lumen would constitute an overwhelming risk to 
the host unless rejection could be prevented or perfectly 
controlled with immunosuppressants that were themselves 
inimical to an effective defense against infections or 
neoplasms. 
Thus, life-supporting function of a transplanted human 
bowel had never been achieved until this was accomplished 
with a multivisceral allograft transplanted in Pittsburgh in 
November 1987 to a child who was treated with cyclospo-
rine-based immunosuppression,1 using an experimental op-
eration described in 1960.43,44 Although the child died after 
6 months of a posttransplant B-cell lymphoma,1 enteral 
feeding provided adequate nutrition for most of the survival 
period. Then, in August 1988, DeItz et al2 ofKiel, Germany, 
transplanted a small bowel segment from a live donor to a 
patient who ate during much of a 56-month survival. During 
the succeeding 15 months, Grant et al3 from London, On-
tario, and Margreiter et al4 of Innsbruck added three more 
long-surviving intestine-containing composite grafts (n = 2 
and 1, respectively), and on March 18, 1989, Goulet et al5 
performed a cadaveric intestine-only transplantation in a 
child. Although the latter patient is the only one still alive 
from this era, the two Canadian recipients survived for 5 
years. 
These cases, combined with an extensive experience with 
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upper abdominal exenteration and reconstruction with 
"cluster" allografts that contained segments of stomach, 
duodenum, and jejunum,4S,46 established the feasibility of 
transplanting hollow abdominal viscera. The next step came 
with the report by Murase et al47 at the 1989 European 
Society of Organ Transplantation meeting in Barcelona that 
rat bowel, transplanted alone or as part of a multi visceral 
complex under a short course of treatment with the new 
drug, tacrolimus, could be routinely engrafted. When the 
superior efficacy of tacrolimus in rats was promptly con-
firmed in other rat intestinal transplant models,48,49 the 
University of Pittsburgh program of clinical intestinal trans-
plantation was begun on May 2, 1990.10 
The linchpin of immunosuppression in all subsequent 
cases consisted of tacrolimus and variable-dose prednisone. 
During the ensuing II years, a variety of adjunct agents 
with different cellular/molecular targets have been added at 
the time of surgery: cyclophosphamide, mycophenolate 
mofetil, the interleukin-2 receptor antagonist daclizumab, 
and most recently sirolimus. With the possible exception of 
daclizumab, the additional drugs have not dramatically im-
proved either survival or the ease of management. Conse-
quently, we have looked to strategies beyond more potent 
immunosuppressive drug regimens as a means of improving 
the outlook for intestinal recipients. 
Such strategies have been based on insight into the im-
munologic events leading to engraftment of all organs that 
began with the key observation by Murase et alSO that the 
intestine-alone and multivisceral allografts of rats treated 
with tacrolimus become genetic composites within 14 days 
after transplantation. With the aid of immunocytochemical 
stains that differentiated donor from recipient cells, the 
leukocytes of the lamina propria and elsewhere, including 
those in the donor mesenteric lymph nodes, were identified 
as those of the recipient. so The rat findings were promptly 
confirmed by Iwaki et aisl in human intestine-only and 
multi visceral recipients. 
It had been known for nearly 20 years that this kind of 
leukocyte replacement occurred in human hepatic allo-
grafts, but it had been assumed to be a special quality of 
liver transplants. Now, it was realized that leukocyte re-
placement must be a generic phenomenon with the accep-
tance of all kinds of whole organ allografts.6,sl Within the 
following year, the further studies of leukocyte migration 
and persistence in the host (i.e., microchimerism) that had 
begun with research on intestinal transplantationso,s2-s4 
eventually matured to the paradigm that defined events after 
the transplantation of all organs in terms of a mutually 
canceling double immune reaction in which the two cell 
popUlations reciprocally modulated immune responsive-
ness, inducing variable levels of mutual nonreactivity.ss-s7 
In appropriate inbred rat strain combinations (e.g., Brown 
Norway and Lewis), it has been possible to separate the 
contemporaneous graft-versus-host and host-versus-graft 
arms of the double immune reaction. S4,58 It has been shown 
that the quantity and lineage profiles of the passenger leu-
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kocytes contained in different kinds of organ grafts strongly 
influence the relative strengths of the interactive host-ver-
sus-graft and graft-versus-host reactions, the quantity and 
lineages of the chimerism found in the recipients, graft 
survival, and graft function.54.58.59 As a practical consider-
ation, the passenger leukocytes of the liver and bone mar-
row cells, both of which include large numbers of immature 
leukocytes and cells of myeloid origin, have been shown to 
be more tolerogenic, with a lower risk of GVHD, than the 
intestinal passenger leukocytes, which are rich in mature 
lymphocytes. 59 
In accordance with this concept, Murase et al60 have 
shown in exquisitely controlled rat studies that chronic 
rejection of intestinal allografts can be prevented by infus-
ing donor bone marrow cells. Moreover, in GVHD-prone 
strain combinations, the GVHD is prevented with low-dose 
irradiation of the bowel, whereas chronic rejection of these 
irradiated grafts can be prevented with concomitant donor 
bone marrow infusion. The results in the rat experiments 
have guided the use of adjunct donor bone marrow in 39 of 
our human intestinal transplantations, including 9 recent 
cases in which the intestine-alone allograft or the intestinal 
component of multi visceral grafts was conditioned with 
irradiation. 
The cumulative improvement in survival rates during the 
past 11 years has qualified intestine-alone and multi visceral 
transplantation for funding as a service by the Health Care 
Financing Administration as of Oct. 4, 2000. A good view 
of the still-limited world experience can be found in the 
report by Grant et al61 from the International Intestinal 
Transplant Registry. Although it is too early to make defin-
itive assessments of recent management changes, it is note-
worthy that the rate of chronic rejection, late graft loss, and 
delayed death in the bone marrow-augmented recipients has 
been less than in the contemporaneous nonaugmented con-
trols. Moreover, all 10 of the recipients of irradiated grafts 
survive to date, and none has had evidence of any irradia-
tion-associated graft dysfunction. 
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DISCUSSION 
DR. RONALD W. BUSlJITlL (Los Angeles, California): First I would like 
to say that I really feel privileged to have been asked to discuss this 
extraordinary work. Dr. Abu-Elmagd has presented a paper from Dr. 
Starzl's team which I clearly consider a landmark. This body of work 
performed over the past ten years represents a turning point in the devel-
opment of patients who have intestinal failure. Just as the Starzl team 
brought liver replacement from surgical curiosity to worldwide application, 
they have now paved the way for intestinal transplantation. 
This paper is really packed with pearls as a result of the very extensive 
and comprehensive experience the Pittsburgh group has acquired. I really 
believe it is a "must" read for anyone who is interested in intestinal 
replacement. I have several questions that span clinical, technical, and 
immunological issues. 
First, clinical. In the paper you discuss the issue of a salvageable liver 
graft. And I assume that you mean that if you have a patient who has 
potentially reversible liver disease that you will only do an intestinal 
allograft rather than the combined intestinal liver allograft. My question is, 
in a recipient that has portal hypertension, do you find that the portal 
hypertension is a deterrent to good intestinal allograft function alone? And 
in what percentage of those patients do you see substantial recovery in the 
liver function after you replace the intestine? The second question is: 
C-M-V has not been really a problem in our series of liver intestinal 
transplantation because we preemptively treat these patients with ganci-
c10vir based on their PCR. Do you do this? Secondly, do you still not use 
CMV positive donors as you have written about in the past? 
The technical question relates to the hook-up of the native portal vein to 
the portal vein of the allograft when you do a combined liver intestinal 
graft. Sometimes this can be problematic. When do you do that? And when 
do you hook up the native portal vein into the IVC? 
And finally, an immunological question. Your results are very intriguing 
with the irradiation of the allograft and the bone marrow infusion; however, 
it seems to me that this may be at cross purposes since your hypothesis is 
that if you perform bone marrow perfusion you are increasing the amount 
of microchimerism and therefore decreasing. the incidence of both acute 
and chronic rejection. If one irradiates the graft it seems that you would be 
decreasing the amount of passenger cells that would be allowed to migrate 
to the recipient lymph nodes. 
PRESENTER DR. KAREEM ABU-ELMAOD (Pittsburgh, Pennsylvania): 
Thank you, Dr. Busuttil, for your generous comments. Your first clinical 
question concerning the type of allograft that should be used for intestinal 
graft candidates with portal hypertension, and the outcomes in those who 
received intestine only is an important and practical one. Currently, there 
are no published data to guide the transplant physicians in making this 
decision. Based upon our cumulative experience, the type and degree of 
portal hypertension and the extent of associated liver damage are the main 
determining factors. Patients with extensive postmesenteric thrombosis are 
usually not candidates for isolated intestine and should be considered for 
either combined liver-intestinal or multi visceral transplantation, particu-
larly when the thrombotic process involves the splenic vein. The degree of 
portal hypertension is assessed by the conventional clinical, biochemical, 
and endoscopic parameters including the splenic size and the platelet count. 
Gastroesophageal varices and ascites are less likely to develop in patients 
with short gut syndrome because of the reduced or absent mesenteric 
arterial flow. The extent of hepatocellular injury and liver damage is 
determined histopathologically. In general, patients with modest portal 
hypertension (mild splenic enlargement, platelet count >50,000, no gas-
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troesophageal varices and minimal to moderate portal fibrosis without 
severe intrahepatic cholestasis) can be considered for intestinal only 
transplantation. 
In 62 (68%) of our primary intestine only recipients, the pretransplant 
liver biopsy showed mild to moderate portal fibrosis with serum bilirubin 
ranging from normal to 21 mgldl. In all of these recipients, the serum 
bilirubin normalized within the first 4-8 weeks after surgery and the 
implanted grafts functioned well except for those that were lost to intrac-
table rejection. It is important to mention that in patients with significant 
portal hypertension, the venous out flow of the isolated intestinal allografts 
was drained into the recipient systemic circulation via the inferior vena 
cava. The histopathologic reversibility of the TPN induced hepatic damage 
in these recipients, particularly those with long-term full gastrointestinal 
nutritional autonomy, is currently under evaluation. 
As for the second question about CMV, we monitor all of our transplant 
patients including the intestinal recipients as described in the manuscript, 
with weekly pp65 antigenemia test. at very frequent intervals during the 
first 8-12 postoperative weeks. The use of CMV positive grafts was 
avoided only in CMV negative intestine-alone or modified multi visceral 
recipients unless there was an urgent need for transplantation. 
The technical question relating to the hook-up of the native portal vein 
to the portal vein of the liver-intestinal graft is also a valid one. In all of the 
liver-intestinal recipients, a portocaval shunt was initially performed before 
dissecting the residual native abdominal viscera. the purpose was to de-
compress the mesenteric collaterals and minimize blood loss. In our early 
experience, we routinely disconnected the shunt shortly after reperfusion 
and anastomosed the end of the native portal vein to the side of the allograft 
portal vein. After the development of portal vein thrombosis in one of our 
pediatric recipients who had a small portal vein (1995), we have accepted 
the physiologic compromise of potential diversion of the insulin rich blood 
away from the transplanted liver and have left the portocaval shunt 
permanently. 
The final question concerning the concept of simultaneous bone marrow 
infusion and intestinal allograft irradiation is an important one. In a series 
of exquisitely controlled rat studies, my colleague Dr. Murase and others 
have shown that the quantity and lineage profiles of the passenger leuko-
cytes contained in different organ grafts strongly influence the quantity and 
lineage of microchimerism, graft survival, and function. In these experi-
ments, the intestinal passenger lymphocytes have been shown to be less 
tolerogenic with a higher risk of GVHD than the passenger leukocytes of 
the liver and bone marrow cells, both of which include large numbers of 
immature leukocytes and cells of myeloid origin. Accordingly, cytoreduc-
tion of the intestinal allograft with low-dose ex-vivo irradiation, which 
removes large numbers of mature T cells, combined with simultaneous 
donor bone marrow cell replacement should improve the clinical outlook of 
intestinal transplantation. This has been shown to reduce the risk of 
rejection without risk of GVHD in our preclinical studies. 
DR. ANDREAS G. TZAKls (Miami, Florida): I would like to thank Dr. 
Abu-Elmagd for allowing me to review the manuscript and also congrat-
ulate him for his fine work and presentation. I would like to acknowledge 
that it was Dr. Abu-Elmagd's initiative that brought federal funding to 
intestinal transplantation recently. I have one comment and one question. 
The presentation reflects the continuous innovations and intensity which 
have characterized the Pittsburgh program from the outset. It also shows 
the confusing nature of the results in such an elaborate project. 
There are two clear messages in the paper which I reviewed. The first 
message is that for whatever reason, and probably for a variety of reasons, 
the results in intestinal transplantation are improving over time. And I 
wholeheartedly agree with that. 
The second message in the paper was that the presence of a contempo-
raneously transplanted liver conveys a protective effect in the combined 
liver-intestinal graft. It is offered as an explanation of two findings: the 
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superior long-term results of the combined liver-intestinal grafts in Pitts-
burgh, and the observed increased incidence of acute and chronic rejection 
of isolated grafts. 
Nevertheless, in the same paper, the liver failed to offer a similar 
protection in the liver containing multi visceral grafts. In addition, isolated 
intestinal transplants had the same patient and graft survival at five years, 
which is the last time point where there are meaningful numbers to make 
comparisons. Our own results at the University of Miami indicate that 
liver-intestinal and multi visceral transplants behave similarly and we can-
not distinguish the results between them. 
In regard to isolated intestinal grafts, we have marginally higher inci-
dence of acute rejection, a difference which is disappearing with improving 
immunosuppression. In fact, the overall results are better in our program 
with the isolated intestinal transplants because the patients are less ill, the 
operation is smaller, and the incidence of severe complications is lower. 
Clearly, the combination of bone marrow infusions with radiation treat-
ment of the graft is a revolutionary new approach, and its universal success 
to date may have far-reaching implications. For that reason, I would like to 
elaborate on Dr. Busuttil's question and ask Dr. Abu-Elmagd if he has any 
facts from the human experience regarding chimerism or any other immu-
nological studies to show what actually happens in humans. To my knowl-
edge, the only reported relevant data have only been in small animals. 
DR. KAREEM ABU-ELMAOD: Thank you, Dr. Tzakis, for acknowledging 
my role in the recent approval by the Health Care Financing Administra-
tion (HCFA) of intestinal and multi visceral transplantation for funding as 
a clinical service. Concerning your comment about the immunoprotective 
effect of the liver allograft on the simultaneously transplanted intestine, I 
would like to address a few important points that may help eliminate the 
present confusion and controversy. First, it is obvious from our Kaplan-
Meier (cumulative) survival curves shown in Figure 6 of our manuscript 
that long-term follow-up (beyond 5 years) is needed to demonstrate any 
difference in survival of the three different kinds of the intestinal allografts. 
The lower long-term survival rate of the multi visceral grafts (n=25) 
compared to the combined liver-intestinal grafts (n=75) despite inclusion 
of the liver in 20 of the 25 in the first group and all 75 of the second group, 
could be explained simply by the documented higher risk of PTLD and 
lethal infections among the multi visceral recipients as shown in Table 4 of 
the manuscript and the relatively small number of the multi visceral grafts 
(only II) that survived beyond the 5-year milestone. Second, we agree with 
Dr. Tzakis, we as previously published, that combined liver-intestinal and 
multi visceral recipients belong to a high-risk population because of the 
disease gravity prior to transplantation, added to the complexity of the 
multi visceral operations, and the difficult peri operative management. 
These non-immunologic risk factors partially erode the immunoprotec-
tive advantage of the liver and its positive impact, both in the early and 
overall graft survival. To resolve this debate, it will be necessary for Dr. 
Tzakis to identify those grafts that were lost due to rejection in his series 
and calculate the difference in the cumulative risk from rejection between 
the non-liver and liver cohorts as we showed in Figure 10 of our manu-
script. I believe that with longer follow-up Dr. Tzakis and others will come 
to the same conclusion about the liver's protective effect as we have. 
However, the recent management strategy of combined graft immune-
modulation and induction immunosuppressive therapy with monoclonal 
antibodies may eliminate the difference or even achieve better survival 
after isolated intestinal transplantation by reducing the risk of rejection in 
this low operative risk and more healthy population. 
As to the question about the comparative results of the chimerism and 
other immunologic studies in our recipients who received irradiated intes-
tine and simultaneous bone marrow infusion versus those treated conven-
tionally, we can only say at the present time that the clinical results have 
been encouraging. An analysis of the chimerism, immunologic, and other 
biologic studies will be published when we have more data. 
